Elutia

ELUT · NASDAQ

$0.8105−$0.0047 (−0.58%)TodayMarket closed · Oct 20, 4:00 PM ET

Prev close $0.8152

ELUT analyst rating

This isn't available right now. Refresh to try again.

The case for and against

Updated May 8, 2025

Bull case

Elutia Inc. has demonstrated strong revenue growth in its BioEnvelope product line, with an 18% year-over-year increase to $2.7 million, attributed to the promising initial sales of its EluPro product. The company's gross margin improved significantly by 630 basis points year-over-year, reaching 42.5%, driven by a favorable product mix, while R&D expenses notably decreased by 40%, allowing for more strategic allocation towards growth initiatives. As EluPro transitions to full commercial launch and partners like Boston Scientific begin to sell the product, the company is well-positioned for upward earnings revisions and continued pipeline expansion, indicating strong future growth potential.

Bear case

Elutia Inc., which specializes in regenerative medicine, reported 3Q24 revenue of $5.9 million, falling short of both Cantor and FactSet consensus estimates, reflecting a year-over-year decline of approximately 3%. Notably, revenue from the company's BioEnvelope products decreased by 12%, driven by customers delaying orders for the EluPro product, while revenue from the Cardiovascular segment plummeted 40% to $0.6 million. Furthermore, a slower-than-anticipated sales trajectory, combined with potential regulatory setbacks and the reliance on a limited number of key products, poses significant risks to Elutia’s profitability and overall financial outlook.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.